Protein-based biologics
Accelerating the development, optimisation, and scalability of biologic therapies
Get to market faster with CPI
At CPI, we support the development and optimisation of protein-based biologics, including antibodies, recombinant proteins, and virus-like particles (VLPs). Our continuous processing, regulatory expertise, and state-of-the-art facilities enable you to accelerate from pre-clinical discovery to early-stage development with confidence and precision.
Our capabilities include cell culture, purification, digital modelling, high-throughput analytics, and GMP-ready process development, ensuring your biologic therapies are scalable, efficient, and market-ready. Whether optimising cell culture conditions, purification strategies, or stability, we provide the tools and expertise to de-risk your journey to clinical success.
Protein-based biologics
Accelerating the development, optimisation, and scalability of biologic therapies
Get to market faster with CPI
At CPI, we support the development and optimisation of protein-based biologics, including antibodies, recombinant proteins, and virus-like particles (VLPs). Our continuous processing, regulatory expertise, and state-of-the-art facilities enable you to accelerate from pre-clinical discovery to early-stage development with confidence and precision.
Our capabilities include cell culture, purification, digital modelling, high-throughput analytics, and GMP-ready process development, ensuring your biologic therapies are scalable, efficient, and market-ready. Whether optimising cell culture conditions, purification strategies, or stability, we provide the tools and expertise to de-risk your journey to clinical success.
Protein-based biologics
Accelerating the development, optimisation, and scalability of biologic therapies
Get to market faster with CPI
At CPI, we support the development and optimisation of protein-based biologics, including antibodies, recombinant proteins, and virus-like particles (VLPs). Our continuous processing, regulatory expertise, and state-of-the-art facilities enable you to accelerate from pre-clinical discovery to early-stage development with confidence and precision.
Our capabilities include cell culture, purification, digital modelling, high-throughput analytics, and GMP-ready process development, ensuring your biologic therapies are scalable, efficient, and market-ready. Whether optimising cell culture conditions, purification strategies, or stability, we provide the tools and expertise to de-risk your journey to clinical success.
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Antibody process development and formulation
We provide tailored solutions for antibody production and characterisation, supporting pre-clinical discovery through early-stage development. Our expertise includes:
Cell bank generation and transient expression development.
Upstream and downstream processing at scales up to 200L.
Mammalian expression platforms (CHO, HEK293, MSCs).
Advanced analytical characterisation including QTOF mass spectrometry, SEC-MALS, and glycan analysis.
High-throughput bioprocessing with AMBR bioreactors.
These capabilities ensure optimal titres, purity, and molecular structure, supporting early-stage toxicology, formulation development, and material supply.
Recombinant protein and VLP process development
We accelerate recombinant protein and VLP production with advanced bioprocessing expertise:
Microbial and mammalian expression systems – E. coli, S. cerevisiae, P. Pastoris B. subtilis, CHO, HEK293 and MSCs.
Cell-free protein synthesis for rapid prototyping.
Plasmid stability testing and strain selection for enhanced yield and purity.
Process development at bench to 100L scale.
Downstream purification strategies – optimising recovery and process efficiency.
These capabilities support early-stage discovery, toxicology evaluations, and high-quality material supply for preclinical studies.
Equipment and technology testing (alpha and beta)
De-risk your innovative technology with our industry-leading expertise in benchmarking and process validation. Whether you are a technology vendor in the development stage or a business evaluating a technical piece of equipment, we provide objective and reliable testing in industry-relevant environments.
Alpha and beta testing: Benchmarking new biologics technologies in real-world environments.
Process validation studies: Assessing reproducibility, manufacturability, and yield consistency.
Side-by-side technology comparisons: Evaluating competing bioprocessing approaches.
Proof-of-concept testing: Ensuring scalable, cost-effective, and high-yield workflows.
Our expertise ensures objective, data-driven validation of new bioprocessing technologies, helping companies make informed investment decisions.
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Antibody process development and formulation
We provide tailored solutions for antibody production and characterisation, supporting pre-clinical discovery through early-stage development. Our expertise includes:
Cell bank generation and transient expression development.
Upstream and downstream processing at scales up to 200L.
Mammalian expression platforms (CHO, HEK293, MSCs).
Advanced analytical characterisation including QTOF mass spectrometry, SEC-MALS, and glycan analysis.
High-throughput bioprocessing with AMBR bioreactors.
These capabilities ensure optimal titres, purity, and molecular structure, supporting early-stage toxicology, formulation development, and material supply.
Recombinant protein and VLP process development
We accelerate recombinant protein and VLP production with advanced bioprocessing expertise:
Microbial and mammalian expression systems – E. coli, S. cerevisiae, P. Pastoris B. subtilis, CHO, HEK293 and MSCs.
Cell-free protein synthesis for rapid prototyping.
Plasmid stability testing and strain selection for enhanced yield and purity.
Process development at bench to 100L scale.
Downstream purification strategies – optimising recovery and process efficiency.
These capabilities support early-stage discovery, toxicology evaluations, and high-quality material supply for preclinical studies.
Equipment and technology testing (alpha and beta)
De-risk your innovative technology with our industry-leading expertise in benchmarking and process validation. Whether you are a technology vendor in the development stage or a business evaluating a technical piece of equipment, we provide objective and reliable testing in industry-relevant environments.
Alpha and beta testing: Benchmarking new biologics technologies in real-world environments.
Process validation studies: Assessing reproducibility, manufacturability, and yield consistency.
Side-by-side technology comparisons: Evaluating competing bioprocessing approaches.
Proof-of-concept testing: Ensuring scalable, cost-effective, and high-yield workflows.
Our expertise ensures objective, data-driven validation of new bioprocessing technologies, helping companies make informed investment decisions.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Antibody process development and formulation
We provide tailored solutions for antibody production and characterisation, supporting pre-clinical discovery through early-stage development. Our expertise includes:
Cell bank generation and transient expression development.
Upstream and downstream processing at scales up to 200L.
Mammalian expression platforms (CHO, HEK293, MSCs).
Advanced analytical characterisation including QTOF mass spectrometry, SEC-MALS, and glycan analysis.
High-throughput bioprocessing with AMBR bioreactors.
These capabilities ensure optimal titres, purity, and molecular structure, supporting early-stage toxicology, formulation development, and material supply.
Recombinant protein and VLP process development
We accelerate recombinant protein and VLP production with advanced bioprocessing expertise:
Microbial and mammalian expression systems – E. coli, S. cerevisiae, P. Pastoris B. subtilis, CHO, HEK293 and MSCs.
Cell-free protein synthesis for rapid prototyping.
Plasmid stability testing and strain selection for enhanced yield and purity.
Process development at bench to 100L scale.
Downstream purification strategies – optimising recovery and process efficiency.
These capabilities support early-stage discovery, toxicology evaluations, and high-quality material supply for preclinical studies.
Equipment and technology testing (alpha and beta)
De-risk your innovative technology with our industry-leading expertise in benchmarking and process validation. Whether you are a technology vendor in the development stage or a business evaluating a technical piece of equipment, we provide objective and reliable testing in industry-relevant environments.
Alpha and beta testing: Benchmarking new biologics technologies in real-world environments.
Process validation studies: Assessing reproducibility, manufacturability, and yield consistency.
Side-by-side technology comparisons: Evaluating competing bioprocessing approaches.
Proof-of-concept testing: Ensuring scalable, cost-effective, and high-yield workflows.
Our expertise ensures objective, data-driven validation of new bioprocessing technologies, helping companies make informed investment decisions.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Antibody process development and formulation
We provide tailored solutions for antibody production and characterisation, supporting pre-clinical discovery through early-stage development. Our expertise includes:
Cell bank generation and transient expression development.
Upstream and downstream processing at scales up to 200L.
Mammalian expression platforms (CHO, HEK293, MSCs).
Advanced analytical characterisation including QTOF mass spectrometry, SEC-MALS, and glycan analysis.
High-throughput bioprocessing with AMBR bioreactors.
These capabilities ensure optimal titres, purity, and molecular structure, supporting early-stage toxicology, formulation development, and material supply.
Recombinant protein and VLP process development
We accelerate recombinant protein and VLP production with advanced bioprocessing expertise:
Microbial and mammalian expression systems – E. coli, S. cerevisiae, P. Pastoris B. subtilis, CHO, HEK293 and MSCs.
Cell-free protein synthesis for rapid prototyping.
Plasmid stability testing and strain selection for enhanced yield and purity.
Process development at bench to 100L scale.
Downstream purification strategies – optimising recovery and process efficiency.
These capabilities support early-stage discovery, toxicology evaluations, and high-quality material supply for preclinical studies.
Equipment and technology testing (alpha and beta)
De-risk your innovative technology with our industry-leading expertise in benchmarking and process validation. Whether you are a technology vendor in the development stage or a business evaluating a technical piece of equipment, we provide objective and reliable testing in industry-relevant environments.
Alpha and beta testing: Benchmarking new biologics technologies in real-world environments.
Process validation studies: Assessing reproducibility, manufacturability, and yield consistency.
Side-by-side technology comparisons: Evaluating competing bioprocessing approaches.
Proof-of-concept testing: Ensuring scalable, cost-effective, and high-yield workflows.
Our expertise ensures objective, data-driven validation of new bioprocessing technologies, helping companies make informed investment decisions.
Protein-based biologics
applications
We support innovation across a wide range of biologics applications.
Antibodies.
Recombinant proteins.
Virus like particles and viral vectors.
mRNA.
Enzymes.
Recombinant vaccines.
Microbiome therapeutics and biosimilars.
Phage.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Demonstrate the benefits of your biologics innovation
We provide the expertise, tools, and infrastructure to accelerate early-stage development and support investment readiness with:
Rapid, cost-effective product and process development for securing early-stage funding.
Validation of biologics function in industry-relevant settings for investor confidence.
Optimisation of new biologics integration into product pipelines for competitive advantage.
Prove manufacturability and scalability
Ensure your biologic therapies are reproducible, scalable, and sustainable with our process development expertise. With CPI, you can access:
Early-stage manufacturability assessments to evaluate production feasibility.
Process optimisation to enhance efficiency, yield, and cost-effectiveness.
Scalable biomanufacturing processes for clinical and commercial readiness.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure funding and commercial partnerships. We support with:
Commercial feasibility assessments for biologics production.
Validation of scale-up processes to attract investment and licensing opportunities.
Transitioning from pre-clinical development to market launch.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-ready infrastructure for biologics manufacturing.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to reduce risk and accelerate time-to-market.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We facilitate:
Access to world-class biologics manufacturers and academic institutions.
Connections to supply chains and commercial production partners.
Strategic collaborations for long-term biologics market growth.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Demonstrate the benefits of your biologics innovation
We provide the expertise, tools, and infrastructure to accelerate early-stage development and support investment readiness with:
Rapid, cost-effective product and process development for securing early-stage funding.
Validation of biologics function in industry-relevant settings for investor confidence.
Optimisation of new biologics integration into product pipelines for competitive advantage.
Prove manufacturability and scalability
Ensure your biologic therapies are reproducible, scalable, and sustainable with our process development expertise. With CPI, you can access:
Early-stage manufacturability assessments to evaluate production feasibility.
Process optimisation to enhance efficiency, yield, and cost-effectiveness.
Scalable biomanufacturing processes for clinical and commercial readiness.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure funding and commercial partnerships. We support with:
Commercial feasibility assessments for biologics production.
Validation of scale-up processes to attract investment and licensing opportunities.
Transitioning from pre-clinical development to market launch.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-ready infrastructure for biologics manufacturing.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to reduce risk and accelerate time-to-market.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We facilitate:
Access to world-class biologics manufacturers and academic institutions.
Connections to supply chains and commercial production partners.
Strategic collaborations for long-term biologics market growth.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Demonstrate the benefits of your biologics innovation
We provide the expertise, tools, and infrastructure to accelerate early-stage development and support investment readiness with:
Rapid, cost-effective product and process development for securing early-stage funding.
Validation of biologics function in industry-relevant settings for investor confidence.
Optimisation of new biologics integration into product pipelines for competitive advantage.
Prove manufacturability and scalability
Ensure your biologic therapies are reproducible, scalable, and sustainable with our process development expertise. With CPI, you can access:
Early-stage manufacturability assessments to evaluate production feasibility.
Process optimisation to enhance efficiency, yield, and cost-effectiveness.
Scalable biomanufacturing processes for clinical and commercial readiness.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure funding and commercial partnerships. We support with:
Commercial feasibility assessments for biologics production.
Validation of scale-up processes to attract investment and licensing opportunities.
Transitioning from pre-clinical development to market launch.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-ready infrastructure for biologics manufacturing.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to reduce risk and accelerate time-to-market.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We facilitate:
Access to world-class biologics manufacturers and academic institutions.
Connections to supply chains and commercial production partners.
Strategic collaborations for long-term biologics market growth.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Demonstrate the benefits of your biologics innovation
We provide the expertise, tools, and infrastructure to accelerate early-stage development and support investment readiness with:
Rapid, cost-effective product and process development for securing early-stage funding.
Validation of biologics function in industry-relevant settings for investor confidence.
Optimisation of new biologics integration into product pipelines for competitive advantage.
Prove manufacturability and scalability
Ensure your biologic therapies are reproducible, scalable, and sustainable with our process development expertise. With CPI, you can access:
Early-stage manufacturability assessments to evaluate production feasibility.
Process optimisation to enhance efficiency, yield, and cost-effectiveness.
Scalable biomanufacturing processes for clinical and commercial readiness.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure funding and commercial partnerships. We support with:
Commercial feasibility assessments for biologics production.
Validation of scale-up processes to attract investment and licensing opportunities.
Transitioning from pre-clinical development to market launch.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-ready infrastructure for biologics manufacturing.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to reduce risk and accelerate time-to-market.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We facilitate:
Access to world-class biologics manufacturers and academic institutions.
Connections to supply chains and commercial production partners.
Strategic collaborations for long-term biologics market growth.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
We are over 500 world-class innovation experts, scientists and engineers.
We are over 500 world-class innovation experts, scientists and engineers.
We are over 500 world-class innovation experts, scientists and engineers.
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
Trusted by leading organisations
,
Why choose CPI?
Work with us to defer capital and workforce investments until your product or process is proven at scale.
Expertise in biologics innovation
Proven success in antibody, recombinant protein, and VLP development.
Industry-leading infrastructure
Supporting full-scale biologics manufacturing.
Collaborative approach
We connect you with industry partners, funding opportunities, and regulatory insights to de-risk your journey.
End-to-end support
From early-stage development to full commercialisation.
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Simon Hawdon
Protein-based biologics
Business Development
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Simon Hawdon
Protein-based biologics
Business Development
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Simon Hawdon
Protein-based biologics
Business Development
